ata using the same terms in Chinese, with no time restrictions. The title, abstract, and full text of related articles determined according to these search criteria were carefully reviewed by the authors. Unfortunately, we have found very few articles reporting on fungal co-infections, not only that, some studies have not provided the details of the pathogens. Even so, we found COVID-19 patients, especially severely ill ones or accompanied with immunocompromised state, had co-infections of fungi [7]. In China, Chen et al. performed fungal culture on all 99 COVID-19 patients at admission and found five (5%, 5/99) cases of fungal infection, including one case of Aspergillus flavus, one case of Candida glabrata and three cases of C. albicans [8]. Yang et al. found there (3/52, 5.8%) patients had fungal co-infection in 52 critically ill patients, including A. flavus, A. fumigatus and C. albicans [5]. Other China studies have found a higher percentage of secondary infections (8–15%) in COVID-19 patients, but it is not clear whether it is bacterial or fungal infection [9, 10]. In addition, one study mentioned that 2.8% (31/1099) patients were treated with antifungal medicine, including 1.9% (18/926) non-severe patients and 7.5% (13/173) severe patients, but there was no etiological evidence of fungal co-infection [11]. Another study